Physician profile
Derek M Low
NPI 1245644376
$1,396.22
in general payments reported to CMS, 2019-2025
22 companies · $61.20 in 2025
The $61.20 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $15.72 · 2021: $114 · 2022: $780 · 2023: $293 · 2024: $23.38 · 2025: $61.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $293.18 | 2021-2024 | Tezspire, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.58 | 2022-2023 | Ofev |
| Glaxosmithkline, LLC. | $112.79 | 2022-2023 | Nucala, Trelegy Ellipta |
| Vertex Pharmaceuticals Incorporated | $105.19 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $97.93 | 2022-2025 | Dupixent |
| Baxter Healthcare | $81.11 | 2023 | Hillrom - Life 2000 Ventilation System |
| Amgen INC. | $69.71 | 2022-2023 | Tezspire |
| Insmed, INC. | $67.28 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $50.65 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $40.96 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $39.63 | 2022-2023 | Recarbrio, Zerbaxa |
| Genentech USA, INC. | $25.66 | 2022 | |
| Grifols USA, LLC | $23.90 | 2022 | |
| Ardelyx, INC. | $23.58 | 2025 | Ibsrela |
| Gilead Sciences, INC. | $22.38 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $20.82 | 2021 | |
| Abbvie INC. | $19.64 | 2019 | |
| Mylan Specialty L.P. | $18.99 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.42 | 2023 | |
| Kyowa Kirin, INC. | $14.82 | 2021 | |
| Nabriva Therapeutics, Plc | $12.89 | 2021 | |
| Itamar Medical INC | $8.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Low listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.